22-011039 mchb requires G-CSF mobilized human peripheral blood CD34+ cells in order to for our study about the drug candidates testing of OLFM4 inhibition.
Ended Awarded
- Contract number
- 75N92022F00129
- Awardee
-
Stemcell Technologies Inc. UEI ELPMWCGFK518
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,945
Award facts
- Contract value 100% obligated
- $10,944.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Kent, WA 98032, USA
Award details come from SAM.gov/FPDS.
Quick answers
Who was awarded contract 75N92022F00129?
75N92022F00129 was awarded to Stemcell Technologies Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on May 27, 2022.
How much is contract 75N92022F00129 worth?
The government has obligated $10,945 on 75N92022F00129.
Is contract 75N92022F00129 an order under another contract?
Yes. 75N92022F00129 is a BPA call under HHSN263201500148B, a blanket purchase agreement.
Was contract 75N92022F00129 competed?
The extent of competition for 75N92022F00129 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award